Fairfield, Bush & Co’s ClearPoint Neuro CLPT Stock Holding History

Fairfield, Bush & Co’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-134	Closed	-$910	–	179
2023 Q4	$910	Buy	+134	New	+$759	﹤0.01%	441
2023 Q3	–	Sell	-134	Closed	-$970	–	174
2023 Q2	$970	Buy	+134	New	+$1.14K	﹤0.01%	467
2022 Q3	–	Sell	-134	Closed	-$2K	–	173
2022 Q2	$2K	Buy	+134	New	+$1.37K	﹤0.01%	386

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fairfield, Bush & Co's CLPT Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of ClearPoint Neuro (CLPT) in Q1 2024, closing a stake of 134 shares — an estimated $910 sold.

Fairfield, Bush & Co first reported a position in CLPT in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 81 funds tracked by Wall St. Rank hold CLPT as of Q1 2024.

Fairfield, Bush & Co reported no remaining ClearPoint Neuro position as of Q1 2024 after selling out during the quarter.
Fairfield, Bush & Co sold 134 ClearPoint Neuro shares in Q1 2024, an estimated $910.
Fairfield, Bush & Co first reported a position in ClearPoint Neuro in Q2 2022 and held it in 3 quarters.
Fairfield, Bush & Co's ClearPoint Neuro position peaked at $2K in Q2 2022.
81 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.